March 12th 2024
Findings from the phase 3 ECHELON-3 trial demonstrated that brentuximab vedotin plus lenalidomide and rituximab led to improvements in overall survival among patients with diffuse large B-cell lymphoma.
Community Practice Connections™: Real-World Applications of Novel Therapies Across TNBC and Addressing Disparities in Care
View More
6th Annual Precision Medicine Symposium: An Illustrated Tumor Board
October 18-19, 2024
Register Now!
Advances in TNBC: Communicating with Your Patients About Clinical Trial Awareness and Treatment Concerns to Improve Clinical Outcomes
View More
Community Practice Connections™: 5th Annual Precision Medicine Symposium – An Illustrated Tumor Board
View More
Assessing the Durability, Tolerability of Loncastuximab in R/R DLBCL
February 7th 2024In the second part of a 2-article series, Matthew Matasar, MD, MS, discusses long-term follow up data from the LOTIS-2 trial and how these data show the durability and tolerability of loncastuximab for patients with relapsed/refractory diffuse large B-cell lymphoma.
Read More
Breaking Down Considerations for Tafasitamab/Lenalidomide in DLBCL
January 24th 2024In the first part of a 2-article series, Matthew A. Lunning, DO, FACP, takes into consideration the perspectives of his peers on the use of tafasitamab and lenalidomide for patients with relapsed/refractory diffuse large B-cell lymphoma.
Read More
Considering Tolerability of Regimens for Third-Line DLBCL Therapy
January 13th 2024During a Targeted Oncology™ Case-Based Roundtable™ event, Amitkumar Mehta, MD, discussed what regimens are available for patients who progressed after 2 prior lines of therapy for diffuse large B-cell lymphoma, and what tolerability concerns there are for these regimens.
Read More
ADC Loncastuximab Shows Signs of Durable Response in R/R DLBCL
January 10th 2024In the first part of a 2-article series, Matthew Matasar, MD, MS, discusses where loncastuximab fits into the treatment of patients with relapsed/refractory diffuse large B-cell lymphoma and the data that led to the antibody drug conjugate’s approval.
Read More
Bispecific Agents Vs Loncastuximab as Third-Line Therapy for R/R DLBCL
January 5th 2024During a Targeted Oncology™ Case-Based Roundtable™ event, Paolo Strati, MD, discussed treatment selection and sequencing of loncastuximab in the context of new bispecific T-cell engagers. This is the second of 2 articles based on this event.
Read More
Tafasitamab/Lenalidomide in R/R DLBCL Shows Benefit with Long-Term Use
December 26th 2023In the second article of a 2-part series, Hayder Saeed, MD, discusses the long-term use of tafasitamab and lenalidomide in patients with diffuse large B-cell lymphoma and how the combination therapy compares in the real-world setting.
Read More
Dose-Escalation/Expansion Trial Evaluates NX-1607 Across Cancer Settings
December 11th 2023An ongoing phase 1a/1b trial is set to evaluate NX-1607-101, an oral small-molecule inhibitor of casitas B-lineage lymphoma B designed to enhance innate and adaptive immune responses and demonstrate antitumor activity and long-term survival in patients with persistent lymphoma including those with diffuse large B-cell lymphoma.
Read More
Odronextamab Continues to Appear Safe, Effective in Patients With R/R DLBCL
December 10th 2023In the final analysis of the phase 2 ELM-2 trial, odronextamab monotherapy showed encouraging efficacy, with a manageable safety profile in patients with relapsed/refractory diffuse large B-cell lymphoma.
Read More
Axi-cel Improves OS vs SOC in Older Patients With Large B-Cell Lymphoma
December 10th 2023Results from the phase 3 ZUMA-7 trial showed superior progression-free survival and overall survival in patients 65 and older with large B-cell lymphoma with axicabtagene ciloleucel compared with standard of care.
Read More
Khan Discusses Third-Line Novel Treatment Approaches for R/R DLBCL
December 10th 2023During a Targeted Oncology™ Case-Based Roundtable™ event, Cyrus M. Khan, MD, and participants discussed the case of a patient with diffuse large B-cell lymphoma who progressed after complete remission on standard-of-care frontline therapy, then had stable disease after receiving polatuzumab vedotin, bendamustine, and rituximab.
Read More
Discussing Subgroup Responses to Immunotherapy and R-CHOP in DLBCL
December 6th 2023In the second article of a 2-part series, Herbert A. Eradat, MD, discusses further considerations with adding polatuzumab vedotin in combination chemotherapy in certain subgroups of patients with diffuse large B-cell lymphoma.
Read More
Timing of DLBCL Relapse Linked With Evolutionary Patterns
December 1st 2023A report suggests the cause behind different outcomes among patients with diffuse large B-cell lymphoma who relapse, highlighting that patients whose cancer relapses shortly after treatment tend to have worse responses to additional chemotherapy-based treatment.
Read More
Updated Data Show Efficacy of Tafasitamab/Lenalidomide in R/R DLBCL
November 28th 2023In the first article of a 2-part series, Hayder Saeed, MD, discusses the 5-year follow up data from the L-MIND study, which shows the continuing efficacy of tafasitamab and lenalidomide for patients with relapsed/refractory diffuse large B-cell lymphoma.
Read More
Immunotherapy in Addition to R-CHOP Improves a SOC in DLBCL
November 15th 2023In the first article of a 2-part series, Herbert A. Eradat, MD, discusses the research down that led to the use of the immunotherapy polatuzumab vedotin in combination with chemotherapy for patients with diffuse large B-cell lymphoma.
Read More
Lunning Discusses Defining and Approaching Treatment for Early-Relapsed DLBCL
October 10th 2023During a Targeted Oncology™ Case-Based Roundtable™ event, Matthew A. Lunning, DO, and participants discussed how they approach treatment for a patient with diffuse large B-cell lymphoma who relapsed 8 months after primary therapy.
Read More
Bispecific T-Cell Engagers Emerge as Later-Line Therapies for DLBCL
October 2nd 2023During a Targeted Oncology™ Case-Based Roundtable™ event, Medhi H. Hamadani, MD, discussed the bispecific T-cell engagers epcoritamab and glofitamab and how they fit into the treatment algorithm for patients with diffuse large B-cell lymphoma. This is the second of 2 articles based on this event.
Read More
Phillips Discusses Treatment Options for Early-Relapsed DLBCL
September 22nd 2023During a Targeted Oncology™ Case-Based Roundtable™ event, Tycel J. Phillips, MD, and participants discussed treatment options for a patient with diffuse large B-cell lymphoma who progressed after 8 months on first-line therapy and prefers to receive outpatient therapy.
Read More
Reviewing Options After CAR T-Cell Therapy Progression in R/R DLBCL
September 20th 2023During a Targeted Oncology™ Case-Based Roundtable™ event, Mehdi H. Hamadani, MD, discussed the efficacy of therapies for diffuse large B-cell lymphoma after progression on chimeric antigen receptor T-cell therapy. This is the first of 2 articles based on this event.
Read More